Posted by Michael Wonder on 19 Apr 2021
Citrine Medicine and Sinopharm Group announce strategic partnership to broaden and accelerate access to rare disease drugs in China
19 April 2021 - Citrine Medicine and Sinopharm Group today announced a strategic partnership to accelerate the commercialisation of rare disease drugs in China.
The two companies will work together to build a rare disease ecosystem in China and enable the availability of more rare disease therapies to Chinese patients in need.
As part of the collaboration, Sinopharm Group will support Citrine in building a supply chain and securing distribution channels for delivering innovative rare disease therapies to patients in need. Sinopharm Group has more than 1,000 branches and subsidiaries, covering 388 prefecture-level cities in 31 provinces in China, enabling the company to reach patients in urban and rural regions across China.
